We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bacterial Strain Type and Biomarkers Predict Mortality

By LabMedica International staff writers
Posted on 08 Aug 2013
Clostridium difficile genotype predicts mortality after C. difficile infection (CDI), and excess mortality correlates with genotype-specific changes in biomarkers.

The relationship between the specific bacterial strain types with changes in the host’s biomarkers strongly implicates inflammatory pathways as a factor in poor outcomes after CDI.

Scientists at the John Radcliffe Hospital (Oxford, UK) used multilocus sequence typing (MSLT) on strains isolated from C. difficile toxin enzyme immunoassay (EIA)-positive fecal samples from September 2006 to May 2011. The study involved 2,745 toxin-positive and 27,550 toxin-negative strains. The C. difficile toxin enzyme immunoassay used was from Meridian Bioscience (Cincinnati, OH, USA).

Overall, 14-day mortality was 13% in patients with EIA-positive samples versus 5% with EIA-negative samples. Strain polymerase chain reaction (PCR) ribotype 078/ST 11 was associated with the highest mortality at 25%, followed by PCR ribotype 27/ST 1 at 20%. Across a variety of blood or serum markers, the authors also found a significant variance in mean baseline neutrophil counts by genotype, and EIA-positivity versus EIA-negativity. Overall, biomarkers predicted 30% to 40% of strain-specific mortality differences.

Threshold levels of serum albumin equal to or less than 24.5 g/L, C- reactive protein (CRP) greater than 228 mg/L, white cell count (WBC) greater than 12 × 103 /µL, and increased respiratory rates were associated with an increased risk of all-cause mortality. A simple four variable prediction rule was devised based on these threshold levels and when tested on the initial data.

The authors concluded that MLST demonstrates that strain predicts mortality and severity biomarkers at both clade and individual sequence-type level. For patient monitoring, neutrophils/WBC ratios, CRP, and albumin are the key as C. difficile–associated biomarkers that are highly prognostic for short-term mortality. The study was published in the August 15, 2013, edition of the journal Clinical Infectious Diseases.

Related Links:

John Radcliffe Hospital

Meridian Bioscience



New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.